However, tumor cells compete with cDC1s for glutamine in the tumor microenvironment via the SLC38A2 transporter, thus impeding cDC1 function and evading T cell-mediated killing (Guo et al. 2023). This evidence concerns the gene SLC38A2 and neoplasm.